Show Summary Details
- Foreword
- Preface
- Acknowledgements
- Symbols and abbreviations
- Section 1 Pulmonary hypertension in context
- Chapter 1 History of pulmonary hypertension (PH) and the circulation
- Chapter 2 Definitions of PH and PAH
- Chapter 3 The Dana Point (2008) clinical classification of PH
- Chapter 4 Prognosis of PAH
- Section 2 Pathology, pathobiology, and pathophysiology of PAH
- Chapter 5 Pathology of PAH
- Chapter 6 Pathology of pulmonary veno-occlusive disease and pulmonary capillary haemangiomatosis
- Chapter 7 Pathology of PH due to left heart disease
- Chapter 8 Pathology of PH due to lung diseases and/or hypoxia
- Chapter 9 Pathology of chronic thromboembolic pulmonary hypertension
- Chapter 10 Pathology of PH with unclear and/or multifactorial mechanisms
- Chapter 11 Pathobiology of PAH
- Chapter 12 Pathophysiology of PH in non-PAH groups
- Chapter 13 Inflammation, growth factors, and thrombosis in PAH
- Chapter 14 The pressure loaded right ventricle
- Section 3 Genetics, epidemiology, and risk factors
- Chapter 15 Genetics and genomics of PAH
- Chapter 16 Epidemiology of PAH and PH
- Chapter 17 Epidemiology and management of PAH in PVOD and/or PCH
- Chapter 18 Drugs and toxins and PAH
- Section 4 PAH associated conditions
- Chapter 19 CTD-associated PAH
- Chapter 20 PAH associated with HIV
- Chapter 21 PAH associated with portal hypertension (portopulmonary hypertension)
- Chapter 22PAH associated with congenital systemic-to-pulmonary cardiac shunts
- Chapter 23 PAH associated with schistosomiasis
- Chapter 24 PAH associated with chronic haemolytic anaemias
- Section 5 Haemodynamics and treatment approaches in PH due to left heart disease
- Chapter 25 Haemodynamics and treatment approaches in PH due to left heart disease
- Section 6 PH due to chronic lung diseases and/or hypoxia
- Chapter 26 Lung disease-associated PH
- Section 7 Venous thromboembolism, acute pulmonary embolism, and chronic thromboembolic pulmonary hypertension
- Chapter 27 Venous thromboembolism
- Chapter 28 Acute pulmonary embolism and investigations
- Chapter 29 Chronic thromboembolic pulmonary hypertension
- Section 8 Diagnosis and investigations in PAH
- Chapter 30 Diagnosis and investigations in PAH
- Section 9 Management of PAH
- Chapter 31 General approach to the management of PAH
- Chapter 32 Specific therapies for PAH
- Index
(p. 1) Pulmonary hypertension in context
(p. 1)
Pulmonary hypertension in context
Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.
Please subscribe or login to access full text content.
If you have purchased a print title that contains an access token, please see the token for information about how to register your code.
For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.
- Foreword
- Preface
- Acknowledgements
- Symbols and abbreviations
- Section 1 Pulmonary hypertension in context
- Chapter 1 History of pulmonary hypertension (PH) and the circulation
- Chapter 2 Definitions of PH and PAH
- Chapter 3 The Dana Point (2008) clinical classification of PH
- Chapter 4 Prognosis of PAH
- Section 2 Pathology, pathobiology, and pathophysiology of PAH
- Chapter 5 Pathology of PAH
- Chapter 6 Pathology of pulmonary veno-occlusive disease and pulmonary capillary haemangiomatosis
- Chapter 7 Pathology of PH due to left heart disease
- Chapter 8 Pathology of PH due to lung diseases and/or hypoxia
- Chapter 9 Pathology of chronic thromboembolic pulmonary hypertension
- Chapter 10 Pathology of PH with unclear and/or multifactorial mechanisms
- Chapter 11 Pathobiology of PAH
- Chapter 12 Pathophysiology of PH in non-PAH groups
- Chapter 13 Inflammation, growth factors, and thrombosis in PAH
- Chapter 14 The pressure loaded right ventricle
- Section 3 Genetics, epidemiology, and risk factors
- Chapter 15 Genetics and genomics of PAH
- Chapter 16 Epidemiology of PAH and PH
- Chapter 17 Epidemiology and management of PAH in PVOD and/or PCH
- Chapter 18 Drugs and toxins and PAH
- Section 4 PAH associated conditions
- Chapter 19 CTD-associated PAH
- Chapter 20 PAH associated with HIV
- Chapter 21 PAH associated with portal hypertension (portopulmonary hypertension)
- Chapter 22PAH associated with congenital systemic-to-pulmonary cardiac shunts
- Chapter 23 PAH associated with schistosomiasis
- Chapter 24 PAH associated with chronic haemolytic anaemias
- Section 5 Haemodynamics and treatment approaches in PH due to left heart disease
- Chapter 25 Haemodynamics and treatment approaches in PH due to left heart disease
- Section 6 PH due to chronic lung diseases and/or hypoxia
- Chapter 26 Lung disease-associated PH
- Section 7 Venous thromboembolism, acute pulmonary embolism, and chronic thromboembolic pulmonary hypertension
- Chapter 27 Venous thromboembolism
- Chapter 28 Acute pulmonary embolism and investigations
- Chapter 29 Chronic thromboembolic pulmonary hypertension
- Section 8 Diagnosis and investigations in PAH
- Chapter 30 Diagnosis and investigations in PAH
- Section 9 Management of PAH
- Chapter 31 General approach to the management of PAH
- Chapter 32 Specific therapies for PAH
- Index